Abstract
LBA1 Combined expression of FOXC1, MKI67, and PDL1 predicts efficacy of immune checkpoint inhibitor therapy and hyperprogressive disease risk in advanced/metastatic renal cell cancer: Validation in the Javelin 101 clinical trial cohort
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
